All In Biotech

NDA 203255 · Recordati Rare

Signifor Lar Kit

Pasireotide Pamoate · Intramuscular

Orphan

Last checked: Nov 20, 2026Latest source record: Jul 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Dec 15, 2014

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1

0 Phase 3, 1 recruiting

FAERS reports

1,502

1,066 serious, 103 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 16, 2024.

SIGNIFOR LAR is a somatostatin analog indicated for the treatment of: Patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. ( 1.1 ) Patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. ( 1.2 ) 1.1 Acromegaly SIGNIFOR LAR is indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. 1.2 Cushing's Disease SIGNIFOR LAR is indicated for the treatment of patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

Mechanism: SIGNIFOR LAR is an injectable cyclohexapeptide, somatostatin analog. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTR). There are 5 known human somatostatin receptor subtypes: SSTR 1, 2, 3, 4, and 5. These receptor subtypes are expressed in different tissues under normal physiological conditions. Somatostatin analogs bind to SSTRs with different potencies. Pasireotide binds with high affinity to 4 of the 5 SSTRs (see Table 4). Table 4 – Binding Affinities of Somatostatin (SRIF-14) and Pasireotide to the Five Human SSTR Subtypes (SSTR 1-5) Results are...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 29, 2018 Supplement 4 · Efficacy OrphanLabelLetter
  • Dec 15, 2014 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
5 products under this application
  • SIGNIFOR LAR KIT · PASIREOTIDE PAMOATE EQ 10MG BASE/VIAL · FOR SUSPENSION, INTRAMUSCULAR · Prescription
  • SIGNIFOR LAR KIT · PASIREOTIDE PAMOATE EQ 40MG BASE/VIAL · FOR SUSPENSION, INTRAMUSCULAR · Prescription
  • SIGNIFOR LAR KIT · PASIREOTIDE PAMOATE EQ 30MG BASE/VIAL · FOR SUSPENSION, INTRAMUSCULAR · Prescription
  • SIGNIFOR LAR KIT · PASIREOTIDE PAMOATE EQ 60MG BASE/VIAL · FOR SUSPENSION, INTRAMUSCULAR · Prescription
  • SIGNIFOR LAR KIT · PASIREOTIDE PAMOATE EQ 20MG BASE/VIAL · FOR SUSPENSION, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pasireotide Pamoate" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased169
  • diabetes mellitus165
  • hyperglycaemia163
  • drug ineffective125
  • diarrhoea121
  • off label use120
  • headache117
  • fatigue105
  • nausea97
  • dizziness72
  • blood pressure increased69
  • asthenia60

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20121
20136
201421
201560
2016139
2017138
2018138
2019128
2020175
202196
2022124
2023157
2024136
2025118
202664

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Recordati Rare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.